SCHEMBL10012992

SCHEMBL10012992

COc1cccc2oc(S)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 5/20 0.44
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 4/20 0.43
HPGD P15428 3/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
MCHR1 Q99705 1/20 0.42
F2RL3 Q96RI0 2/20 0.41
CYP2A6 P11509 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 2/20 0.40
LMNA P02545 2/20 0.40
RAB9A P51151 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
G6PD P11413 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9768577 0.80 NQO2 (0.46) NQO2ALDH1A1KDM4EHPGDMEN1
SCHEMBL20931281 0.80 ELANE (0.49) NQO2ALDH1A1KDM4EHPGDMEN1
SCHEMBL30698496 0.79 ALDH1A1 (0.51) NQO2ALDH1A1KDM4EHPGDMEN1
SCHEMBL27037459 0.79 ALDH1A1 (0.51) NQO2ALDH1A1KDM4EHPGDMEN1
SCHEMBL5036483 0.79 MCHR1 (0.50) NQO2ALDH1A1KDM4EHPGDMEN1
SCHEMBL6612807 0.78 F2RL3 (0.42) NQO2ALDH1A1KDM4EHPGDMEN1
SCHEMBL31213014 0.77 NQO2 (0.43) NQO2ALDH1A1KDM4EHPGDMEN1
SCHEMBL28056277 0.77 ALDH1A1 (0.42) NQO2ALDH1A1KDM4EHPGDMEN1
SCHEMBL29098687 0.77 KDM4E (0.52) ALDH1A1KDM4EHPGDMEN1CYP1A2
SCHEMBL3117868 0.76 F2RL3 (0.48) NQO2ALDH1A1KDM4EHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421222-B2 Substituted quinazolines as HDAC6 inhibitors AUGUSTINE THERAPEUTICS (BE) 2025-09-23 US disclosed
US-20250145604-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2025-05-08 US disclosed
US-20250051319-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2025-02-13 US disclosed
WO-2023118507-A2 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2023-06-29 WO disclosed
US-8753895-B2 Surface modified metal nano-particle and use thereof Postech Academy-Industries Foundation (KR) 2014-06-17 US disclosed
US-20130252274-A1 Surface Modified Metal Nano-Particle and Use Thereof POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2013-09-26 US disclosed
US-20120168681-A1 Surface Modified Metal Nano-Particle and Use Thereof POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051319-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS HDAC6, HDAC9, HDAC1 NQO2 317/4885ALDH1A1 608/4885KDM4E 2750/4885
US-20250145604-A1 COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS HDAC6, HDAC9, HDAC1 NQO2 317/4885ALDH1A1 608/4885KDM4E 2750/4885
US-12421222-B2 Substituted quinazolines as HDAC6 inhibitors HDAC6, HDAC9, HDAC1 NQO2 69/4885ALDH1A1 850/4885KDM4E 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.